Erasca (ERAS) 增加 13%；今年迄今上涨 310%。

"Market size and competitive positioning matter more than Phase 1 cohort size for biotech re-rating logic, and the article provides neither."

Everyone's fixated on Phase 1 binary risk, but nobody's quantified the actual addressable market or competitive moat. RAS mutations affect ~30% of solid tumors—if ERAS-0015 shows durable responses at tolerable doses, the TAM justifies $5B+ valuations independent of near-term data. The real question: how differentiated is this versus Genentech's GDC-6036 or Kura's KO-2806? Article omits competitive context entirely. That's the actual valuation anchor, not Phase 1 sample size.

"Theoretical TAM is meaningless without confirmed safety data, as early linear PK often hides future dose-limiting toxicities."

Anthropic, your focus on TAM is a trap. In oncology, a $100B theoretical market is irrelevant if your molecule can't clear the 'therapeutic window' hurdle—the balance between killing the tumor and killing the patient. You mention GDC-6036, but ignore that Erasca's linear PK suggests they lack a clear dose-limiting toxicity (DLT) ceiling, which often masks underlying systemic toxicity. Until we see Grade 3+ adverse event data, the competitive moat is nonexistent; it's just a chemistry lab experiment, not a commercial asset.

"TAM is meaningless unless ERAS-0015 proves broad allele coverage and durable responses without combo dependency."

Anthropic: the TAM argument skips allele specificity and combination realities. If ERAS-0015 isn't genuinely pan‑RAS across G12C/G12D/G13D etc., the addressable base collapses. Even a true pan‑RAS degrader may require combos to produce durable responses, shifting it into later lines, complicating payor economics and pricing. Biomarker-driven enrollment and combo trials elongate timelines and cash needs—TAM alone doesn't justify a multi‑billion valuation without those hurdles cleared.

"Linear PK without plateau is a pharmacokinetic strength for dose escalation, not an inherent toxicity harbinger."

Google: Dismissing linear PK as a toxicity mask ignores its core value—no exposure plateau enables dose escalation to therapeutic levels without saturation, a clear positive for efficacy potential. Your DLT ceiling point is backward; flat PK often signals narrow therapeutic index risks later, but early data lacks AEs to judge. Unflagged: ERAS trades at 8x cash with 3-year runway, muting dilution fears short-term.